🔗 Share this article

As the United States proceeds with unprecedented changes to its vaccine guidelines, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based physician and epidemiologist who initially gained attention by expressing skepticism about coronavirus vaccinations in the pandemic and has focused upon alleged deaths following Covid immunization in her short position at the FDA.

Planned Shifts to Childhood Immunization Schedule

Health officials were set to announce major changes to the childhood vaccination calendar in December, bringing the US with Denmark’s national calendar, it is understood – a significant shift that would place the US out of step with a large portion of the international standard with no evidence for benefit. This reveal has been pushed back until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to present at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the division this year.

A New Direction at the FDA

Høeg's temporary position might represent a tighter collaboration between the drug and biologics centers as Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for halting certain pediatric vaccine recommendations in the US so as to align more like Denmark's approach, a society with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

In her initial public appearances, she has continued to focus on vaccines – typically the responsibility of Dr. Prasad, director of the FDA’s CBER – rather than medication approval.

Concerns Over Background

Dr. Høeg has little discernible track record in pharmaceutical research, oversight or management, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in managing a large organization. She is not an expert in pharmaceutical oversight.”

Previous directors of the center would “understand legal statutes and the science of drug development”, noted a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that former directors who headed CBER have had.”

This division has an vast range of responsibilities at the FDA, she stated.

“Many people just pays attention on the innovative therapies, but the generic drug division approves a multitude of generic drugs. There’s a biosimilars program, over-the-counter program and other areas, and each of these need to be managed,” Dr. Woodcock said. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative element to the job, which oversees over 5,000 staff members. “It’s a enormous administrative position, if you perform it correctly,” Woodcock concluded.

Agency Reaction and Disputed Programs

Regarding concerns about Dr. Høeg's qualifications and whether this assignment indicates more teamwork among FDA leaders on vaccines, a spokesperson responded that the “inquiries stem from flawed presumptions”.

“This background is consistent with the responsibilities of her job,” the representative explained, citing the period Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg takes over the commissioner’s controversial fast-track approval initiative, a contentious one-day drug-approval program that allegedly worried her preceding directors. “How are these medications being picked for this voucher program? Who makes the decisions?” Howard questioned. “There is a lot of secrecy occurring at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards laxer regulations of pharmaceuticals, aside from immunizations.”

Established Past Work on Immunizations

Concerning immunizations, Høeg has a clearer, if problematic, track record, some experts observe. She published a research paper using unverified crowd-sourced reports to assess the incidence of heart inflammation after COVID-19 vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccinations are more dangerous than they are.

Part of her “desired changes” for the current federal leadership featured altering guidelines for novel immunizations and ending “unnecessary” vaccines, she stated following the vote on a online show. At the FDA, Dr. Høeg has allegedly proposed barring teenage boys from getting COVID-19 vaccines.

“She is an complete true believer who begins with her preconceived notions and reverse-engineers to fit the evidence in a highly deceptive, untruthful way,” Howard said.

Gaining Influence and a “Revenge Tour”

Høeg aligned with fellow contrarians, {like|